These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29463830)

  • 1. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
    Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
    Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
    Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoldering multiple myeloma: natural history and recognition of an evolving type.
    Rosiñol L; Bladé J; Esteve J; Aymerich M; Rozman M; Montoto S; Giné E; Nadal E; Filella X; Queralt R; Carrió A; Montserrat E
    Br J Haematol; 2003 Nov; 123(4):631-6. PubMed ID: 14616966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
    Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
    Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
    Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M
    Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066
    [No Abstract]   [Full Text] [Related]  

  • 6. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
    Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
    Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.
    Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Bladé J; Rosiñol L
    Leukemia; 2018 Sep; 32(9):2082-2094. PubMed ID: 29795240
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.
    Isola I; Moreno DF; Moga E; Mena MP; Tovar N; Rodríguez-Lobato LG; Oliver-Caldés A; Salgado MC; Brasó-Maristany F; Yagüe J; Cibeira MT; Prat A; Rosiñol L; Bladé J; Fernández de Larrea C
    Ann Hematol; 2021 Dec; 100(12):2997-3005. PubMed ID: 34463804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
    Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB
    Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'.
    Lakshman A; Ravi P; Rajkumar SV; Kumar SK
    Leukemia; 2018 Sep; 32(9):2083-2085. PubMed ID: 29802327
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
    Hájek R; Sandecka V; Špička I; Raab M; Goldschmidt H; Beck S; Minařík J; Pavlíček P; Radocha J; Heindorfer A; Jelínek T; Stejskal L; Brožová L; Ševčíková S; Straub J; Pika T; Pour L; Maisnar V; Seckinger A; Hose D
    Br J Haematol; 2020 Jul; 190(2):189-197. PubMed ID: 32163180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.
    Rosiñol L; Carrió A; Bladé J; Queralt R; Aymerich M; Cibeira MT; Esteve J; Rozman M; Campo E; Montserrat E
    Br J Haematol; 2005 Sep; 130(5):729-32. PubMed ID: 16115129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
    Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Østergaard B; Gregersen H; Frølund UC; Andersen NF; Helleberg C; Andersen KT; Pedersen RS; Pedersen P; Abildgaard N; Gimsing P;
    Eur J Haematol; 2016 Sep; 97(3):303-9. PubMed ID: 26710662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
    Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
    Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
    Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
    Am J Hematol; 2021 Mar; 96(3):E63-E65. PubMed ID: 33264449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.